Myelofibrosis (MF) is a hematological malignancy characterized by disrupted blood cell production and bone marrow scarring. Incyte’s ruxolitinib (Jakafi, approved November 2011) and Bristol Myers…
MARKET OUTLOOK Idiopathic pulmonary fibrosis (IPF) is an orphan disease affecting approximately 50,000 people in the United States. It is characterized by an irreversible loss of lung function,…
NASH has the potential to be a large and lucrative therapy market owing to the prevalence of the disease and the lack of approved agents. Patients with NASH are at risk of liver fibrosis,…
Diabetic macular edema (DME) represents the second-largest ophthalmology market for intravitreal anti-VEGF therapies, including Roche / Novartis’s Lucentis and Regeneron / Bayer’s market-…
Diabetic macular edema (DME) represents the second-largest ophthalmology market for intravitreal anti-VEGF therapies, including Roche / Novartis’s Lucentis and Regeneron / Bayer’s market-…
Obesity is a significant public health concern in the United States and Europe. Its chronic progression is associated with type 2 diabetes and adverse cardiovascular (CV) health. Following a series…
MARKET OUTLOOK Atherosclerotic cardiovascular disease (ASCVD) broadly covers coronary artery disease, including acute coronary syndrome, a history of myocardial infarction, stable or unstable…
The 2016/17 FDA approvals of five immune checkpoint inhibitors for platinum-treated patients have significantly altered the treatment landscape for advanced bladder cancer, which has historically…
Atopic dermatitis (AD) is a chronic inflammatory skin disease marked by pruritus and eczema; the main goals of treatment are to protect the skin barrier, reduce inflammation, and alleviate itch…
Peripheral arterial disease (PAD) is a common manifestation of systemic atherosclerosis affecting the arteries in the lower extremities. This condition is considered a major marker for systemic…
DRG expects the next ten years to be transitional for patients with hemophilia A, with and without inhibitors, as both the number of therapy options and size of the hemophilia market increase. With…
Copy/Paste the key inputs from the product brochure, per guidance from Marketing. The axial spondyloarthritis (AxSpA) market boasts biologics representing two distinct drug classes, the…
Diabetic nephropathy (DN), also referred to as diabetic kidney disease, is a common complication of diabetes. The current standard of care fails to halt the frequent progression of DN to kidney…
Although Ofev and Esbriet are welcome options in the treatment armamentarium for idiopathic pulmonary fibrosis (IPF), therapies that can further delay or reverse disease progression, preserve lung…
The Crohn’s disease (CD) therapy market is expected to see increasing use of biologics / targeted oral therapies and grow steadily over the next decade. The well-established TNF-α inhibitors (e…